Vanguard Group Inc. Invests $793.28 Million in Medline $MDLN

Vanguard Group Inc. bought a new position in shares of Medline (NASDAQ:MDLN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 18,887,568 shares of the company’s stock, valued at approximately $793,278,000. Vanguard Group Inc. owned approximately 1.44% of Medline at the end of the most recent quarter.

Several other large investors have also bought and sold shares of MDLN. Perigon Wealth Management LLC acquired a new position in Medline in the fourth quarter valued at approximately $211,000. SteelPeak Wealth LLC acquired a new position in Medline in the fourth quarter valued at approximately $441,000. Sound Income Strategies LLC acquired a new position in Medline in the fourth quarter valued at approximately $25,000. Massachusetts Financial Services Co. MA acquired a new position in Medline in the fourth quarter valued at approximately $429,544,000. Finally, Baillie Gifford & Co. acquired a new position in Medline in the fourth quarter valued at approximately $437,236,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MDLN shares. BNP Paribas Exane started coverage on shares of Medline in a report on Monday, January 12th. They issued a “neutral” rating and a $38.00 price objective on the stock. TD Cowen started coverage on shares of Medline in a report on Monday, January 12th. They issued a “buy” rating on the stock. Stifel Nicolaus set a $55.00 target price on shares of Medline in a research note on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medline in a research note on Monday, January 12th. They issued a “hold” rating and a $40.00 target price for the company. Finally, Barclays started coverage on shares of Medline in a research note on Monday, January 12th. They issued an “overweight” rating and a $50.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medline has an average rating of “Moderate Buy” and an average target price of $50.62.

Medline Stock Up 0.6%

Shares of NASDAQ:MDLN opened at $44.75 on Friday. The firm has a 50 day moving average price of $44.81. Medline has a 52 week low of $34.89 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. On average, research analysts anticipate that Medline will post 1.46 EPS for the current year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.